ArticleTherapeutic advances in gastroenterology2025

Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma.

Huimin Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.